Bruker Corporation (BRKR) Price Target Raised to $65 by JPMorgan

JPMorgan analyst Casey Woodring raised the price target on Bruker Corporation (BRKR) to $65 from $45 on June 8, maintaining an 'Overweight' rating. Bruker recently reported advancements in its microbiology and infection diagnostics portfolio at ASM Microbe 2026 on June 4. The company has updated its MALDI Biotyper CA System, which can now spot 549 clinically validated microbial species. They also introduced new research tools covering 5,325 species aimed at improving diagnostic workflows, which could enhance clinical decision-making.